The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization
Open accessAbstract
BACKGROUND: Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization. RESULTS: Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations. CONCLUSIONS: This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Modeled FE gp120 trimers. a) Model of unliganded FE gp120 trimer containing the truncated V1/V2 stem loop in a “closed” conformation (Upper and lower panels). Top and front views showing the closed conformation of an HIV-1 FE gp120 trimer. We were unable to model the recently solved complete V1/V2 domain onto the unliganded trimer model due to steric clashes; however, a portion of the truncated V1/V2 domain, the V1/V2 stem loop (dark blue), can be seen in a “closed” conformation near the center of the trimer. More structural information is needed regarding the unliganded full-length gp120 trimer to determine precisely where the complete V1/V2 domain is positioned in this conformation; however, owing to its flexibility, the V1/V2 domain will likely also be positioned near the center of the trimer. This is also consistent with cryo-electron tomography studies [26,28]. b) Model of CD4 bound FE gp120 trimer containing the complete V1/V2 domain in an “open” conformation. Top and front views showing the open conformation of the trimer upon binding the CD4 receptor. We were able to graft the complete V1/V2 domain (dark blue) onto the gp120 core. Upon CD4 binding, the V1/V2 domain rotates outwardly in an “open” orientation, consistent with cryo-electron tomography studies [26,28].](/paper-figures/8eb30c01abf24da48ae25dfd264f4cb7/a-systematic-study-of-the-n-glycosylation-sites-of-hiv-1-envelope-protein-on-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike HIV-1 Env, which contains ~25 glycosylation sites [101], and forms a “glycan shield” protecting the virus from neutralizing antibodies [102], HTLV-1 Env contains only five sites for N-glycan attachment [103].”
From HIV-1 and HTLV-1 Transmission Modes: Mechanisms and Importance for Virus Spread (2022) · cites this paper as [101]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwong, P. D., Wyatt, R. T., Robinson, J. E., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,963
Antibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L., Phogat, S., Chan-hui, P., Wagner, D., Pham, P., Goss, J. L., Wrin, T., Simek, M., Fling, S., Mitcham, J., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,849
Atomic structure of the ectodomain from HIV-1 gp41
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., & Wiley, D. C. (1997) · Nature · doi:10.1038/387426a0 · Cited by 1,625
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
Wyatt, R. T., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1884 · Cited by 1,605
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I. S., Wu, X., Yang, Z., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,123
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P. B., Greene, K., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,077
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rüker, F., & Katinger, H. W. D. (1993) · Journal of Virology · doi:10.1128/jvi.67.11.6642-6647.1993 · Cited by 1,011
Leonard, C. K., Spellman, M. W., Riddle, L. M., Harris, R. J., Thomas, J. N., & Gregory, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86956-3 · Cited by 986
Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design
Saphire, E. O., Parren, P. W. H. I., Pantophlet, R. A., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R., & Wilson, I. A. (2001) · Science · doi:10.1126/science.1061692 · Cited by 959
Research works printed but not linked: 1
- Human Retroviruses and AIDS 1989: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Edited by: Myers GRA, Josephs SF, Smith TF, Wong-Staal F, Berzofsky JA. 1989, Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory
Cited by
Sorted by citations
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420
Self-citationCryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
Lyumkis, D., Julien, J., de Val, N., Cupo, A., Potter, C. S., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., Carragher, B. O., et al. (2013) · Science · doi:10.1126/science.1245627 · Cited by 683
Exploitation of glycosylation in enveloped virus pathobiology
Watanabe, Y., Bowden, T. A., Wilson, I. A., & Crispin, M. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.05.012 · Cited by 489
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103154118 · Cited by 429
SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020) · doi:10.1101/2020.12.28.424451
“The introduction of a glycan is a well-known immunogenic escape strategy described in influenza (29), HIV-1 and other viruses (30-32), although to our knowledge this finding presents the first patient-derived escape mutant utilizing this mechanism for SARS-CoV-2.”
Global aspects of viral glycosylation
Bagdonaite, I., & Wandall, H. H. (2018) · Glycobiology · doi:10.1093/glycob/cwy021 · Cited by 234
Current status on the development of pseudoviruses for enveloped viruses
Li, Q., Liu, Q., Huang, W., Li, X., & Wang, Y. (2017) · Reviews in Medical Virology · doi:10.1002/rmv.1963 · Cited by 167
Self-citationThe Importance of Glycans of Viral and Host Proteins in Enveloped Virus Infection
Li, Y., Liu, D., Wang, Y., Su, W., Liu, G., & Dong, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638573 · Cited by 140
Self-citationThe HIV glycan shield as a target for broadly neutralizing antibodies
Doores, K. J. (2015) · FEBS Journal · doi:10.1111/febs.13530 · Cited by 131
Pritchard, L. K., Spencer, D. I. R., Royle, L., Bonomelli, C., Seabright, G. E., Behrens, A., Kulp, D. W., Menis, S., Krumm, S. A., Dunlop, D. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms8479 · Cited by 125
Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies
Shivatare, S. S., Chang, S., Tsai, T.-I., Tseng, S. Y., Shivatare, V. S., Lin, Y., Cheng, Y., Ren, C., Lee, C.-C. D., Pawar, S., et al. (2016) · Nature Chemistry · doi:10.1038/nchem.2463 · Cited by 122
Mapping mutational effects along the evolutionary landscape of HIV envelope
Haddox, H. K., Dingens, A. S., Hilton, S. K., Overbaugh, J. M., & Bloom, J. D. (2018) · eLife · doi:10.7554/elife.34420 · Cited by 129
Haddox, H. K., Dingens, A. S., & Bloom, J. D. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006114 · Cited by 94
Liu, Q., Fan, C., Li, Q., Zhou, S., Huang, W., Wang, L., Sun, C., Wang, M., Wu, X., Ma, J., et al. (2017) · Scientific Reports · doi:10.1038/srep45552 · Cited by 87
Self-citationVisualization of the HIV-1 Env glycan shield across scales
Berndsen, Z. T., Chakraborty, S., Wang, X., Cottrell, C. A., Torres, J. L., Diedrich, J. K., López, C. A., Yates, J. R., van Gils, M. J., Paulson, J. C., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000260117 · Cited by 86
McCoy, L. E., Falkowska, E., Doores, K. J., Le, K. M., Sok, D., van Gils, M. J., Euler, Z., Burger, J. A., Seaman, M. S., Sanders, R. W., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005110 · Cited by 86
Xiang, Q., Li, L., Wu, J., Tian, M., & Fu, Y. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.126993 · Cited by 80
Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM
Antanasijevic, A., Sewall, L. M., Cottrell, C. A., Carnathan, D. G., Jimenez, L. E., Ngo, J. T., Silverman, J. B., Gröschel, B., Georgeson, E., Bhiman, J. N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25087-4 · Cited by 71
HIV-1 and HTLV-1 Transmission Modes: Mechanisms and Importance for Virus Spread
Kalinichenko, S., Komkov, D., & Mazurov, D. (2022) · Viruses · doi:10.3390/v14010152 · Cited by 68
“Unlike HIV-1 Env, which contains ~25 glycosylation sites [101], and forms a “glycan shield” protecting the virus from neutralizing antibodies [102], HTLV-1 Env contains only five sites for N-glycan attachment [103].”
BackgroundBagdonaite, I., Nordén, R., Joshi, H. J., King, S. L., Vakhrushev, S. Y., Olofsson, S., & Wandall, H. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721746 · Cited by 68
Wibmer, C. K., Gorman, J., Ozorowski, G., Bhiman, J. N., Sheward, D. J., Elliott, D. H., Rouelle, J. A., Smira, A. R., Joyce, M. G., Ndabambi, N., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006074 · Cited by 64
Bagdonaite, I., Nordén, R., Joshi, H. J., Dabelsteen, S., Nyström, K., Vakhrushev, S. Y., Olofsson, S., & Wandall, H. H. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004784 · Cited by 56
The external domains of the HIV-1 envelope are a mutational cold spot
Geller, R., Domingo‐Calap, P., Cuevas, J. M., Rossolillo, P., Negroni, M., & Sanjuán, R. (2015) · Nature Communications · doi:10.1038/ncomms9571 · Cited by 57
Seabright, G. E., Cottrell, C. A., van Gils, M. J., D’Addabbo, A., Harvey, D. J., Behrens, A., Allen, J. D., Watanabe, Y., Scaringi, N., Polveroni, T. M., et al. (2020) · Structure · doi:10.1016/j.str.2020.04.022 · Cited by 52
Wang, W., Li, Q., Wu, J., Hu, Y., Wu, G., Yu, C., Xu, K., Liu, X., Wang, Q., Huang, W., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1957720 · Cited by 50
Self-citationBalla-Jhagjhoorsingh, S. S., Corti, D., Heyndríckx, L., Willems, E., Vereecken, K., Davis, D. A., & Vanham, G. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068863 · Cited by 46
Strategies to induce broadly protective antibody responses to viral glycoproteins
Krammer, F. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1299576 · Cited by 41
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Veillette, M., Coutu, M., Richard, J., Batraville, L.-A., Désormeaux, A., Roger, M., & Finzi, A. (2014) · Journal of Visualized Experiments · doi:10.3791/51995 · Cited by 40
Raška, M., Czerneková, L., Moldoveanu, Z., Zachová, K., Elliott, M. C., Novák, Z., Hall, S. D., Höelscher, M., Maboko, L., Brown, R., et al. (2014) · AIDS Research and Therapy · doi:10.1186/1742-6405-11-23 · Cited by 35
Beauparlant, D., Rusert, P., Magnus, C., Kadelka, C., Weber, J., Uhr, T., Zagordi, O., Oberle, C. S., Duenas-Decamp, M. J., Clapham, P. R., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006255 · Cited by 35
Mathys, L., François, K. O., Quandte, M., Braakman, I., & Balzarini, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101181 · Cited by 31
Rathore, U., Saha, P., Kesavardhana, S., Kumar, A. A., Datta, R., Sankar, D. S., Das, R., Mascola, J. R., & Varadarajan, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.788919 · Cited by 31
Viral glycoproteomes: technologies for characterization and outlook for vaccine design
Bagdonaite, I., Vakhrushev, S. Y., Joshi, H. J., & Wandall, H. H. (2018) · FEBS Letters · doi:10.1002/1873-3468.13177 · Cited by 30
Leemans, A., Boeren, M., der Gucht, W. V., Martinet, W., Caljon, G., Maes, L. J. R. M., Cos, P., & Delputte, P. (2019) · Virus Research · doi:10.1016/j.virusres.2019.04.006 · Cited by 31
Rasheed, M., Bettadapura, R., & Bajaj, C. (2015) · Structure · doi:10.1016/j.str.2015.03.026 · Cited by 32
Antigenic variations of recent street rabies virus
Wang, W., Ma, J., Nie, J., Li, J., Cao, S., Wang, L., Yu, C., Huang, W., Li, Y., Yu, Y., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1683436 · Cited by 28
Self-citationEsmaeilzadeh, E., Etemad, B., Lavine, C. L., Garneau, L., Li, Y., Regan, J., Wong, C., Sharaf, R. R., Connick, E., Volberding, P. A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4490 · Cited by 28
Yen, P.-J., Herschhorn, A., Haim, H., Salas, I., Gu, C., Sodroski, J., & Gabuzda, D. H. (2014) · Journal of Virology · doi:10.1128/jvi.02785-13 · Cited by 28
Arms Race between Enveloped Viruses and the Host ERAD Machinery
Frabutt, D. A., & Zheng, Y. (2016) · Viruses · doi:10.3390/v8090255 · Cited by 26
Synthetic Carbohydrate Chemistry and Translational Medicine
Shivatare, S. S., & Wong, C. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c01834 · Cited by 29
Liang, Y., Guttman, M., Williams, J. A., Verkerke, H., Alvarado, D., Hu, S.-L., & Lee, K. K. (2016) · Journal of Virology · doi:10.1128/jvi.01116-16 · Cited by 27
Bioinformatic Analysis of HIV-1 Entry and Pathogenesis
Aiamkitsumrit, B., Dampier, W., Antell, G. C., Rivera, N., Martín‐García, J., Pirrone, V., Nonnemacher, M. R., & Wigdahl, B. L. (2014) · Current HIV Research · doi:10.2174/1570162x12666140526121746 · Cited by 27
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses
Thimmiraju, S. R., Kimata, J. T., & Pollet, J. B. K. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2299380 · Cited by 24
HIV-1 Envelope Glycan Moieties Modulate HIV-1 Transmission
Shen, R., Raška, M., Bimczok, D., Novák, J., & Smith, P. D. (2014) · Journal of Virology · doi:10.1128/jvi.02164-14 · Cited by 25
Defining HIV-1 Envelope N-Glycan Microdomains through Site-Specific Heterogeneity Profiles
Hargett, A. A., Wei, Q., Knoppová, B., Hall, S. D., Huang, Z., Prakash, A., Green, T. J., Moldoveanu, Z., Raška, M., Novák, J., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01177-18 · Cited by 22
Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1
Behrens, A., Struwe, W. B., & Crispin, M. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1376658 · Cited by 24
Zheng, L., Ma, Y., Chen, M., Wu, G., Yan, C., & Zhang, X. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.053 · Cited by 21
Mathys, L., & Balzarini, J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130621 · Cited by 21
HIV-1 pseudoviruses constructed in China regulatory laboratory
Nie, J., Huang, W., Liu, Q., & Wang, Y. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1702479 · Cited by 20
Self-citationSchorcht, A., Cottrell, C. A., Pugach, P., Ringe, R. P., Han, A. X., Allen, J. D., van den Kerkhof, T. L. G. M., Seabright, G. E., Schermer, E. E., Ketas, T. J., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01552-21 · Cited by 20
Heredia, J. D., Park, J., Choi, H. S. J., Gill, K. S., & Procko, E. (2019) · Journal of Virology · doi:10.1128/jvi.00219-19 · Cited by 17
Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection
Xu, M., Qian, K., Shao, H., Yao, Y., Nair, V., Ye, J., & Qin, A. (2021) · Journal of Virology · doi:10.1128/jvi.01549-21 · Cited by 18
Mannose-specific plant and microbial lectins as antiviral agents: A review
Gupta, A., Yadav, K., Yadav, A., Ahmad, R., Srivastava, A., Kumar, D., Khan, M. A., & Dwivedi, U. N. (2024) · Glycoconjugate Journal · doi:10.1007/s10719-023-10142-7 · Cited by 19
Ferreira, R.-C., Grant, O. C., Moyo-Gwete, T., Dorfman, J. R., Woods, R. J., Travers, S. A. A., & Wood, N. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-33390-2 · Cited by 17
Olech, M., & Kuźmak, J. M. (2021) · Viruses · doi:10.3390/v13122529 · Cited by 17
Wang, W., Zirkle, B., Nie, J., Ma, J., Gao, K., Chen, X. S., Huang, W., Kong, W., & Wang, Y. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000595 · Cited by 16
Self-citationHIV-1 Entry and Prospects for Protecting against Infection
Bruxelle, J.-F., Trattnig, N., Mureithi, M., Landais, E., & Pantophlet, R. A. (2021) · Microorganisms · doi:10.3390/microorganisms9020228 · Cited by 16
Kaulfuß, M., Wensing, I., Windmann, S., Hrycak, C. P., & Bayer, W. (2017) · Retrovirology · doi:10.1186/s12977-017-0336-7 · Cited by 14
Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes
Gach, J. S., Mara, K. J. V., LaBranche, C. C., van Gils, M. J., McCoy, L. E., Klasse, P. J., Montefiori, D. C., Sanders, R. W., Moore, J. P., & Forthal, D. N. (2019) · Journal of Virology · doi:10.1128/jvi.01188-19 · Cited by 14
Aiamkitsumrit, B., Sullivan, N. T., Nonnemacher, M. R., Pirrone, V., & Wigdahl, B. L. (2015) · Advances in virus research · doi:10.1016/bs.aivir.2015.04.001 · Cited by 14
Nogal, B., Bowman, C. A., & Ward, A. B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.808352 · Cited by 13
Xu, J. C., Zhang, P., Kusakabe, T., Mon, H., Li, Z., Zhu, L., Iiyama, K., Banno, Y., Morokuma, D., & Lee, J. M. (2015) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2015.07.003 · Cited by 13
Kumar, R., Pan, R., Upadhyay, C., Mayr, L. M., Cohen, S., Wang, X.-H., Balasubramanian, P., Nadas, A. J., Seaman, M. S., Zolla‐Pazner, S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01280-15 · Cited by 12
Hikichi, Y., Yokoyama, M., Takemura, T., Fujino, M., Kumakura, S., Maeda, Y., Yamamoto, N., Sato, H., Matano, T., & Murakami, T. (2016) · Journal of General Virology · doi:10.1099/jgv.0.000536 · Cited by 11
Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies
Wei, Q., Hargett, A. A., Knoppová, B., Duverger, A. E., Rawi, R., Shen, C., Farney, S. K., Hall, S. D., Brown, R., Keele, B. F., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101711 · Cited by 11
Va, M., & Morozov, A. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212398 · Cited by 11
Mathys, L., & Balzarini, J. M. (2014) · Retrovirology · doi:10.1186/preaccept-5732415801310430 · Cited by 11
HIV-1 Entry Mechanisms: Protein-Host Receptor Interactions and Membrane Fusion Dynamics
Elalouf, A., Elalouf, H., & Maoz, H. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl37412 · Cited by 11
Liang, S. A., Ratnayake, P. U., Keinath, C., Jia, L., Wolfe, R., Ranaweera, A., & Weliky, D. P. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b00753 · Cited by 10
Beltrán-Pavez, C., Ferreira, C. B., Merino-Mansilla, A., Fabra-García, A., Casadellà, M., Noguera-Julián, M., Paredes, R., Olvera, À., Haro, I., Brander, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208345 · Cited by 9
Bauer, A. P., Podola, L., Mann, P., Missanga, M., Haule, A., Sudi, L., Nilsson, C., Kaluwa, B., Lueer, C., Mwakatima, M., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00730-17 · Cited by 9
Radford, C. E., & Bloom, J. D. (2025) · Journal of Virology · doi:10.1128/jvi.00195-25 · Cited by 8
Wang, S., Li, W., Wen, J., Wang, L., Tiwari, S. K., Bray, W., Wu, L., Li, N., Hui, H., Clark, A. E., et al. (2025) · mBio · doi:10.1128/mbio.02930-25 · Cited by 10
Self-citationGlycosylation in viral hepatitis
Gruszewska, E., Grytczuk, A., & Chrostek, L. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.129997 · Cited by 8
Mullins, J. I., Deng, W., Giorgi, E. E., Magaret, C. A., Rolland, M., Tanmoy Bhattacharya, A., Westfall, D. H., Yssel, A., Bumgarner, R. E., Murrell, B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73496-0 · Cited by 7
Glycan Nanostructures of Human Coronaviruses
Guo, W., Lakshminarayanan, H., Rodriguez‐Palacios, A., Salata, R. A., Xu, K., & Draz, M. S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s302516 · Cited by 7
Pseudotyped Viruses for Retroviruses
Solomon, M., & Liang, C. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-0113-5_4 · Cited by 7
Zhao, J., Song, E., Huang, Y., Yu, A., & Mechref, Y. S. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00587 · Cited by 7
Kitawi, R. C., W., H., Aman, R. A., Ogutu, B. R., Muigai, A. W. T., Kokwaro, G. O., & Ochieng, W. (2017) · Virology Journal · doi:10.1186/s12985-017-0703-y · Cited by 6
Huang, J., Wang, H., Chen, Y., Wang, P.-S., Lin, S.-J., Chang, Y.-S., Liu, K.-F., & Lo, C. (2020) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2020.103667 · Cited by 6
Ding, C., Patel, D., Ma, Y., Mann, J. F. S., Wu, J., & Gao, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697683 · Cited by 6
Maphumulo, N. F., & Gordon, M. L. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1388729 · Cited by 5
Envelope Gene Evolution and HIV-1 Neuropathogenesis
Vázquez-Santiago, F. J., & Rivera‐Amill, V. (2015) · Journal of Neuroinfectious Diseases · doi:10.4172/2314-7326.s2-003 · Cited by 6
Zhuang, M., Vassell, R. A., Chen, Y., Keller, P. W., Ling, H., Wang, W., & Weiss, C. D. (2019) · Journal of Virology · doi:10.1128/jvi.00142-19 · Cited by 4
Self-citationN-Glycans Modulate HIV-1 Env Conformational PlasticityPreprint
Shehata, M., Casalino, L., Duquette, M., Chen, S., Flaherty, A., Villa, E., & Amaro, R. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.26.645577 · Cited by 4
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates
Fabrizio, C., Bavaro, D. F., Scudeller, L., Lepore, L., Balena, F., Lagioia, A., Angarano, G., Monno, L., & Saracino, A. (2019) · Virology · doi:10.1016/j.virol.2019.07.019 · Cited by 3
Differential selection in HIV-1 gp120 between subtype B and East Asian variant B’
Dang, S., Wang, Y., Budeus, B., Verheyen, J., Yang, R., & Hoffmann, D. E. (2014) · Virologica Sinica · doi:10.1007/s12250-014-3389-y · Cited by 3
Self-citationWang, H., Yang, L., Li, Y., Li, B., Zhu, X., Yan, D., Li, M., Wu, W., Sun, M., & Yang, R. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198424 · Cited by 3
Zhang, D., Liu, Z., Wang, W., Chen, M., Hou, J., Zhang, Z., Ren, W., Ren, L., & Hao, Y. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.02.021 · Cited by 3
Self-citationNatural infection as a blueprint for rational HIV vaccine design
van Haaren, M. M., van den Kerkhof, T. L. G. M., & van Gils, M. J. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1232785 · Cited by 3
de Azevedo, S. S. D., Côrtes, F. H., Villela, L. M., Hoagland, B., Grinsztejn, B. G. J., Veloso, V. G., Morgado, M. G., & Bello, G. (2023) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760230066 · Cited by 2
Lumngwena, E. N., Shuping, L., Bernitz, N., & Woodman, Z. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4375-0 · Cited by 2
Intra-Patient Evolution of HIV-2 Molecular Properties
Palm, A. A., Esbjörnsson, J., Kvist, A., Månsson, F., Biague, A. J., Norrgren, H., Jansson, M., & Medstrand, P. (2022) · Viruses · doi:10.3390/v14112447 · Cited by 2
Production of a new variant of soluble trimer Env of HIV-1 CRF63_02A6 SOSIP.664
Борисовна, Р. Н., Рудометов, А. П., Fando, A. A., Vahitov, D. I., Ilyichev, A. A., Agafonov, A. P., & Карпенко, Л. И. (2024) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-590 · Cited by 2
Lombardi, F., Nakamura, K. J., Chen, T., Sobrera, E. R., Tobin, N. H., & Aldrovandi, G. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128116 · Cited by 2
Glycosylation in HIV-1 Envelope Glycoprotein and its Biological Implications
Ho, Y. S., & Saksena, N. K. (2013) · Future Virology · doi:10.2217/fvl.13.64 · Cited by 2
Specific Substitutions in Region V2 of gp120 env confer SHIV Neutralisation Resistance
Pısıl, Y., Yazıcı, Z., Shida, H., Matsushita, S., & Miura, T. (2020) · Pathogens · doi:10.3390/pathogens9030181 · Cited by 2
Ahmed, S., Shrivastava, T., Kumar, R., Kumar, M., Banerjee, M., Kumar, N., Bansal, M., Das, S., & Samal, S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129733 · Cited by 2
Stagnoli, S., & Abrescia, N. G. A. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4722-6_11 · Cited by 1
Defining criteria for broadly neutralizing HIV antibodies
David‐Fung, E., Belobrajdic, K., Macke, J. P., Quackenbush, C. R., Ganguly, K., & Mamrosh, J. L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1624020 · Cited by 1
Metadata
- Authors
- Wang, W., Nie, J., Prochnow, C., Truong, C., Jia, Z., Wang, S., Chen, X. S., & Wang, Y.
- Affiliations
- National Institutes for Food and Drug Control (CN)
- University of Southern California (US)
- Corresponding author
- Wang, Youchun
- Venue
- Retrovirology
- Published
- 2013-02-06
- Volume
- 10
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1742-4690 (ISSN-L)
- PMC
- PMC3648360
- OpenAlex
- W2137366946
- Cited by
- 114
- References
- 64
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 6 · 2023: 4 · 2022: 5 · 2021: 16 · 2020: 8 · 2019: 9 · 2018: 8 · 2017: 11 · 2016: 8 · 2015: 13 · 2014: 8 · 2013: 4
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Retrovirology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (GM087986)
- National Institute of General Medical Sciences (GM087986, R01GM087986)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- HIV-1 envelope glycoprotein, N-glycosylation sites, viral infectivity, antibody neutralization, CRF07_BC, V1V2 loop, gp41, CD4 binding site, monoclonal antibodies, PG9, homology modeling, HIV-1 clade B
- MeSH terms
- Glycosylation, Humans, Neutralization Tests, Virus Replication, HIV Antibodies, HIV-1, env Gene Products, Human Immunodeficiency Virus, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review